 |
 |

COMMENTS AND OPINIONS
Vitamin D Treatment in Chronic Kidney Disease: What We Really Need to Know
Pierre Delanaye, MD;
Jean-Marie Krzesinski, MD, PhD;
Etienne Cavalier, MD
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
 |
 |
We read with great interest the article by Kovesdy et al1 about the association between activated vitamin D (calcitriol) treatment and mortality in chronic kidney disease (CKD). The results are certainly of interest, but as the study is purely observational, these data must be confirmed on prospective randomized studies. At the end of the article, the authors are calling for such randomized studies comparing activated vitamin D and analogues. We have another proposal and working hypothesis that would involve a study comparing active vitamin D (1,25-dihydroxyvitamin D3 [1,25{OH}2-D3]) with native vitamin D (25-hydroxyvitamin D [25{OH}D]). Indeed, 25(OH)D can bind and directly activate vitamin D receptor. Even if 25(OH)D is 200 to 400 times less active than activated vitamin D, many studies suggest important physiological roles for native vitamin D, even in patients receiving hemodialysis.2 On one hand, circulating 25(OH)D plasma . . . [Full Text of this Article] AUTHOR INFORMATION
CiteULike Connotea Del.icio.us Digg Reddit Technorati
What's this?
RELATED ARTICLE
Association of Activated Vitamin D Treatment and Mortality in Chronic Kidney Disease
Csaba P. Kovesdy, Shahram Ahmadzadeh, John E. Anderson, and Kamyar Kalantar-Zadeh
Arch Intern Med. 2008;168(4):397-403.
ABSTRACT
| FULL TEXT
RELATED LETTERS
Vitamin D Therapy and Reduced Mortality in Chronic Kidney Disease
Hari Kumar K. V. S., Kirtikumar D. Modi, and Ratan Jha
Arch Intern Med. 2008;168(18):2045-2046.
EXTRACT
| FULL TEXT
Vitamin D Therapy and Reduced Mortality in Chronic Kidney Disease—Reply
Csaba Kovesdy, Shahram Ahmadzadeh, John Anderson, and Kamyar Kalantar-Zadeh
Arch Intern Med. 2008;168(18):2046.
EXTRACT
| FULL TEXT
|